OptiNose (OPTN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OptiNose (OPTN) has a cash flow conversion efficiency ratio of -0.027x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.67 Million) by net assets ($-61.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OPTN net asset quality score to measure how much of total assets are equity-financed.
OptiNose - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how OptiNose's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check OPTN cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
OptiNose Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OptiNose ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samwha Electri
KO:009470
|
0.025x |
|
Bapcor Ltd
AU:BAP
|
0.032x |
|
Chyang Sheng Dyeing & Finishing Co Ltd
TW:1463
|
-0.037x |
|
MIC Electronics Limited
NSE:MICEL
|
0.001x |
|
Renascor Resources Ltd
AU:RNU
|
0.003x |
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLACF
|
-0.003x |
|
GEA Grenobl. Elect.
PA:GEA
|
0.134x |
|
Cibus Global LLC
NASDAQ:CBUS
|
-0.324x |
Annual Cash Flow Conversion Efficiency for OptiNose (2015–2024)
The table below shows the annual cash flow conversion efficiency of OptiNose from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market value of OptiNose.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-40.36 Million | $-44.89 Million | 1.112x | +369.11% |
| 2023-12-31 | $-86.61 Million | $-20.53 Million | 0.237x | -80.16% |
| 2022-12-31 | $-56.62 Million | $-67.65 Million | 1.195x | -66.19% |
| 2021-12-31 | $-21.77 Million | $-76.94 Million | 3.534x | +127.82% |
| 2020-12-31 | $6.79 Million | $-86.21 Million | -12.700x | -761.19% |
| 2019-12-31 | $61.58 Million | $-90.81 Million | -1.475x | -90.50% |
| 2018-12-31 | $118.61 Million | $-91.82 Million | -0.774x | -235.46% |
| 2017-12-31 | $154.50 Million | $-35.65 Million | -0.231x | +95.92% |
| 2016-12-31 | $-3.84 Million | $21.72 Million | -5.659x | -635.04% |
| 2015-12-31 | $-27.15 Million | $-28.71 Million | 1.058x | -- |
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well … Read more